Stephens Investment Management Group LLC Has $44.93 Million Stock Holdings in Illumina, Inc. $ILMN

Stephens Investment Management Group LLC lifted its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 15.9% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 342,571 shares of the life sciences company’s stock after purchasing an additional 47,094 shares during the quarter. Stephens Investment Management Group LLC’s holdings in Illumina were worth $44,932,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of ILMN. Empowered Funds LLC grew its holdings in shares of Illumina by 113.7% during the 1st quarter. Empowered Funds LLC now owns 9,284 shares of the life sciences company’s stock worth $737,000 after purchasing an additional 4,940 shares in the last quarter. Sivia Capital Partners LLC acquired a new stake in shares of Illumina during the 2nd quarter worth $621,000. CW Advisors LLC acquired a new stake in shares of Illumina during the 2nd quarter worth $275,000. Marshall Wace LLP grew its holdings in shares of Illumina by 49.0% during the 2nd quarter. Marshall Wace LLP now owns 59,645 shares of the life sciences company’s stock worth $5,691,000 after purchasing an additional 19,618 shares in the last quarter. Finally, Cresset Asset Management LLC grew its holdings in shares of Illumina by 30.9% during the 2nd quarter. Cresset Asset Management LLC now owns 7,404 shares of the life sciences company’s stock worth $706,000 after purchasing an additional 1,748 shares in the last quarter. 89.42% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, SVP Christensen Jakob Wedel sold 700 shares of the company’s stock in a transaction on Wednesday, May 6th. The stock was sold at an average price of $139.04, for a total transaction of $97,328.00. Following the completion of the sale, the senior vice president directly owned 15,056 shares in the company, valued at $2,093,386.24. This represents a 4.44% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith A. Meister sold 104,393 shares of the company’s stock in a transaction on Thursday, May 14th. The stock was sold at an average price of $145.34, for a total value of $15,172,478.62. Following the sale, the director owned 3,500,048 shares of the company’s stock, valued at approximately $508,696,976.32. This represents a 2.90% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 332,530 shares of company stock worth $48,303,655 in the last ninety days. 2.90% of the stock is owned by insiders.

Analysts Set New Price Targets

Several analysts have recently issued reports on ILMN shares. Canaccord Genuity Group reduced their target price on Illumina from $150.00 to $140.00 and set a “hold” rating on the stock in a report on Friday, May 1st. Stifel Nicolaus increased their target price on Illumina from $135.00 to $155.00 and gave the stock a “buy” rating in a report on Tuesday, January 20th. Daiwa Securities Group raised Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 target price on the stock in a report on Thursday. Guggenheim upped their price objective on Illumina from $144.00 to $170.00 and gave the stock a “buy” rating in a research report on Monday, January 26th. Finally, Robert W. Baird set a $137.00 price objective on Illumina in a research report on Friday, February 6th. Seven equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, Illumina has a consensus rating of “Hold” and a consensus target price of $137.75.

Illumina Price Performance

Shares of ILMN stock opened at $142.54 on Friday. The company has a quick ratio of 1.36, a current ratio of 1.75 and a debt-to-equity ratio of 0.56. Illumina, Inc. has a twelve month low of $78.55 and a twelve month high of $155.53. The company has a market cap of $21.57 billion, a P/E ratio of 25.92, a P/E/G ratio of 2.36 and a beta of 1.42. The business has a fifty day simple moving average of $128.58 and a 200 day simple moving average of $129.52.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Thursday, April 30th. The life sciences company reported $1.15 earnings per share for the quarter, topping the consensus estimate of $1.05 by $0.10. Illumina had a return on equity of 31.01% and a net margin of 19.42%.The business had revenue of $1.09 billion during the quarter, compared to the consensus estimate of $1.07 billion. During the same period in the prior year, the company earned $0.97 EPS. Illumina’s revenue for the quarter was up 4.8% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. On average, sell-side analysts forecast that Illumina, Inc. will post 5.2 EPS for the current fiscal year.

Illumina Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.